Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 2/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839527 | 0.75 | BCDIN3D (0.35) | TRPV1FAAHTYK2ABL1 | |
| Hydrochloric Acid SCHEMBL21385193 | 0.73 | TRPV1 (0.39) | TRPV1ABL1CCR4 | |
| Hydrochloric Acid SCHEMBL30568001 | 0.73 | TRPV1 (0.39) | TRPV1ABL1CCR4 | |
| SCHEMBL25347693 | 0.72 | TRPV1 (0.36) | TRPV1FAAHABL1CCR4SYK | |
| SCHEMBL30434319 | 0.72 | TRPV1 (0.36) | TRPV1FAAHABL1CCR4SYK | |
| SCHEMBL25347686 | 0.72 | TRPV1 (0.36) | TRPV1FAAHABL1CCR4SYK | |
| SCHEMBL12540412 | 0.71 | CAMKK1 (0.41) | PDE1APDE1BPDE1CTYK2 | |
| SCHEMBL28696366 | 0.68 | HTR2C (0.51) | PDE1APDE1BPDE1CPDE3BPDE3A | |
| SCHEMBL14849672 | 0.67 | HTR2C (0.49) | — | |
| Trifluoroacetic Acid SCHEMBL14839956 | 0.67 | SSTR4 (0.37) | TRPV1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765751-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, PLK1 | TRPV1 2263/4885FAAH 3330/4885PIM1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.